Impact of Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein in Patients with Hepatitis C Virus-Related Compensated Liver Cirrhosis

被引:15
作者
Hasegawa, Kunihiro [1 ]
Takata, Ryo [1 ]
Nishikawa, Hiroki [1 ]
Enomoto, Hirayuki [1 ]
Ishii, Akio [1 ]
Iwata, Yoshinori [1 ]
Miyamoto, Yuho [1 ]
Ishii, Noriko [1 ]
Yuri, Yukihisa [1 ]
Nakano, Chikage [1 ]
Nishimura, Takashi [1 ]
Yoh, Kazunori [1 ]
Aizawa, Nobuhiro [1 ]
Sakai, Yoshiyuki [1 ]
Ikeda, Naoto [1 ]
Takashima, Tomoyuki [1 ]
Iijima, Hiroko [1 ]
Nishiguchi, Shuhei [1 ]
机构
[1] Hyogo Coll Med, Dept Internal Med, Div Hepatobiliary & Pancreat Dis, Nishinomiya, Hyogo 6638501, Japan
来源
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2016年 / 17卷 / 09期
关键词
hepatitis C virus; liver cirrhosis; hepatocellular carcinoma; Wisteria floribunda agglutinin-positive Mac-2-binding protein (WFA(+)-M2BP); survival; time-dependent receiver operating characteristics (ROC) analysis; HEPATOCELLULAR-CARCINOMA DEVELOPMENT; SUSTAINED VIROLOGICAL RESPONSE; SERUM WFA(+)-M2BP; FIBROSIS; INFECTION; THERAPY; PREDICT; MARKER;
D O I
10.3390/ijms17091500
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We aimed to examine the effect of Wisteria floribunda agglutinin-positive Mac-2-binding protein (WFA(+)-M2BP) level on survival comparing with other laboratory liver fibrosis markers in hepatitis C virus (HCV)-related compensated liver cirrhosis (LC) (n = 165). For assessing prognostic performance of continuous fibrosis markers, we adapted time-dependent receiver operating characteristics (ROC) curves for clinical outcome. In time-dependent ROC analysis, annual area under the ROCs (AUROCs) were plotted. We also calculated the total sum of AUROCs in all time-points (TAAT score) in each fibrosis marker. WFA(+)-M2BP value ranged from 0.66 cutoff index (COI) to 19.95 COI (median value, 5.29 COI). Using ROC analysis for survival, the optimal cutoff point for WFA(+)-M2BP was 6.15 COI (AUROC = 0.79348, sensitivity = 80.0%, specificity = 74.78%). The cumulative five-year survival rate in patients with WFA(+)-M2BP 6.15 COI (n = 69) was 43.99%, while that in patients with WFA(+)-M2BP < 6.15 COI (n = 96) was 88.40% (p < 0.0001). In the multivariate analysis, absence of hepatocellular carcinoma (p = 0.0008), WFA(+)-M2BP < 6.15 COI (p = 0.0132), achievement of sustained virological response (p < 0.0001) and des--carboxy prothrombin < 41 mAU/mL (p = 0.0018) were significant favorable predictors linked to survival. In time-dependent ROC analysis in all cases, WFA(+)-M2BP had the highest TAAT score among liver fibrosis markers. In conclusion, WFA(+)-M2BP can be a useful predictor in HCV-related compensated LC.
引用
收藏
页数:13
相关论文
共 37 条
  • [1] Is the benefit of treating patients with cirrhosis proven?
    Bruno, Savino
    Boccaccio, Vincenzo
    Russo, Maria Luisa
    Maisonneuve, Patrick
    [J]. LIVER INTERNATIONAL, 2016, 36 : 21 - 27
  • [2] Treat chronic hepatitis C virus infection in decompensated cirrhosis - pre- or post-liver transplantation? the ironic conundrum in the era of effective and well-tolerated therapy
    Bunchorntavakul, C.
    Reddy, K. Rajender
    [J]. JOURNAL OF VIRAL HEPATITIS, 2016, 23 (06) : 408 - 418
  • [3] CURRENT CONCEPTS Hepatocellular Carcinoma
    El-Serag, Hashem B.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (12) : 1118 - 1127
  • [4] Predicting progression to cirrhosis in chronic hepatitis C virus infection
    Freeman, AJ
    Law, MG
    Kaldor, JM
    Dore, GJ
    [J]. JOURNAL OF VIRAL HEPATITIS, 2003, 10 (04) : 285 - 293
  • [5] Clinicopathological characteristics and diagnostic performance of Wisteria floribunda agglutinin positive Mac-2-binding protein as a preoperative serum marker of liver fibrosis in hepatocellular carcinoma
    Fujiyoshi, Masato
    Kuno, Atsushi
    Gotoh, Masanori
    Fukai, Moto
    Yokoo, Hideki
    Kamachi, Hirofumi
    Kamiyama, Toshiya
    Korenaga, Masaaki
    Mizokami, Masashi
    Narimatsu, Hisashi
    Taketomi, Akinobu
    [J]. JOURNAL OF GASTROENTEROLOGY, 2015, 50 (11) : 1134 - 1144
  • [6] Evidence-based clinical practice guidelines for liver cirrhosis 2015
    Fukui, Hiroshi
    Saito, Hidetsugu
    Ueno, Yoshiyuki
    Uto, Hirofumi
    Obara, Katsutoshi
    Sakaida, Isao
    Shibuya, Akitaka
    Seike, Masataka
    Nagoshi, Sumiko
    Segawa, Makoto
    Tsubouchi, Hirohito
    Moriwaki, Hisataka
    Kato, Akinobu
    Hashimoto, Etsuko
    Michitaka, Kojiro
    Murawaki, Toshikazu
    Sugano, Kentaro
    Watanabe, Mamoru
    Shimosegawa, Tooru
    [J]. JOURNAL OF GASTROENTEROLOGY, 2016, 51 (07) : 629 - 650
  • [7] Serum Wisteria floribunda agglutinin-positive human Mac-2 binding protein may predict liver fibrosis and progression to hepatocellular carcinoma in patients with chronic hepatitis B virus infection
    Ichikawa, Yuki
    Joshita, Satoru
    Umemura, Takeji
    Shobugawa, Yugo
    Usami, Yoko
    Shibata, Soichiro
    Yamazaki, Tomoo
    Fujimori, Naoyuki
    Komatsu, Michiharu
    Matsumoto, Akihiro
    Tanaka, Eiji
    [J]. HEPATOLOGY RESEARCH, 2017, 47 (02) : 226 - 233
  • [8] Ishii A., 2016, HEPATOL RES, DOI [10.1111/hepr.1270326990490, DOI 10.1111/HEPR.1270326990490]
  • [9] Guideline on the use of new anticancer drugs for the treatment of Hepatocellular Carcinoma 2010 update
    Kaneko, Shuichi
    Furuse, Junji
    Kudo, Masatoshi
    Ikeda, Kenji
    Honda, Masao
    Nakamoto, Yasunari
    Onchi, Morikazu
    Shiota, Goshi
    Yokosuka, Osamu
    Sakaida, Isao
    Takehara, Tetsuo
    Ueno, Yoshiyuki
    Hiroishi, Kazumasa
    Nishiguchi, Shuhei
    Moriwaki, Hisataka
    Yamamoto, Kazuhide
    Sata, Michio
    Obi, Shuntaro
    Miyayama, Shiro
    Imai, Yukinori
    [J]. HEPATOLOGY RESEARCH, 2012, 42 (06) : 523 - 542
  • [10] Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JS']JSH) 2010 Updated Version
    Kudo, Masatoshi
    Izumi, Namiki
    Kokudo, Norihiro
    Matsui, Osamu
    Sakamoto, Michiie
    Nakashima, Osamu
    Kojiro, Masamichi
    Makuuchi, Masatoshi
    [J]. DIGESTIVE DISEASES, 2011, 29 (03) : 339 - 364